Mass spectrometry is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-09-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Aromatic L-amino acid decarboxylase (AADC or AAAD), also known as DOPA decarboxylase (DDC), tryptophan decarboxylase, and 5-hydroxytryptophan decarboxylase, is a lyase enzyme (EC 4.1.1.28), located in region 7p12.2-p12.1.
== Drift gas == The drift gas composition is an important parameter for the IMS instrument design and resolution. Often, different drift gas compositions can allow for the separation of otherwise overlapping peaks. Elevated gas temperature assists in removing ion clusters that may distort experimental measurements.
Red blood cell concentrates are produced either from whole blood or by apheresis. Production from whole blood is far more common than apheresis due to collection and production efficacy as well as economical purposes. When red blood cell concentrates are produced from whole blood, the whole blood is first separated through centrifugation (usually between 3000 to 5000 x g). The red blood cells are denser than plasma and the other present blood cells (platelets, white blood cells) and settle at the bottom of the blood bag. After centrifugation, the red blood cells are separated from the other components (the majority of the plasma, platelets and white blood cells) through the use of an extractor (also referred to as blood press). After extraction, an additive solution is usually added in a ratio of 1:1.5 to 1:2. The purpose of the additive solution is to maintain adequate viscosity, provide nutrients and ATP/GTP building blocks and reduce haemolysis generation throughout blood bank storage. Choice of additive solution has an impact on the red blood cell viability and, thereby, shelf life (expiry date) of the red blood cell concentrate. Usually, shelf life is limited to 4 to 6 weeks, provided that the red blood cell concentrates are stored in adequate conditions (2-6 °C). Commercial additive solutions are typically based on saline. They usually contain glucose, adenine, mannitol and, sometimes, phosphate and guanosine. The additive solution has no, or very little, buffering capacity, but buffering is provided by the red blood cells themselves.
A drug that is not FDA licensed for use in humans, or as a treatment for a particular condition (NLM) A substance that has been tested in a laboratory and has gotten approval from the U.S. Food and Drug Administration (FDA) to be tested in people. A drug may be approved by the FDA for use in one disease or condition but be considered experimental or investigational in other diseases or conditions. Also called investigational drug. (NCI)
Sources: en.wikipedia.org
In 1938 Somogyi published findings showing that excessive insulin can make diabetes management unstable and increase the difficulty of treatment. The Chronic Somogyi rebound, a form of post-hypoglycemic hyperglycemia that Somogyi theorized could occur as a defensive mechanism, is named for him. It can be confused with the Dawn phenomenon and whether or not Somogyi's theory is actually correct is still contested. In 1949, Somogyi argued against the use of high doses of insulin on the grounds that it was a potentially dangerous form of treatment. He also argued that many diabetic patients could successfully manage their conditions through a combination of diet and weight loss. In 1969, Somogyi had a stroke. He died on 21 July 1971.
Brigade Infantry: 1st Battalion (Airborne), 505th Infantry 2nd Battalion (Airborne), 505th Infantry 1st Battalion (Airborne), 508th Infantry Brigade Artillery: 2nd Battalion (Airborne), 321st Artillery (105mm) Brigade Aviation: Company A, 82nd Aviation Battalion Brigade Reconnaissance: Troop B, 1st Squadron (Armored), 17th Cavalry Company O (Ranger), 75th Infantry Brigade Support: 82nd Support Battalion 58th Signal Company Company C, 307th Engineer Battalion (Airborne) 408th Army Security Agency Detachment 52nd Chemical Detachment 518th Military Intelligence Detachment 307th Medical (Airborne) Headquarters and Alpha Company The deployment of the 3rd Brigade took place with significant problems and controversy. In The Rise and Fall of an American Army: US Ground Forces in Vietnam, 1965–1973, author Shelby L. Stanton describes how, other than the 82nd, only two under-strength Marine and four skeletonized Army divisions were left stateside by the beginning of 1968. The U.S. Military Assistance Command, Vietnam (MACV), desperate for additional manpower, wanted the division to deploy to Vietnam, and the Department of the Army, wishing to retain its "sole readily deployable strategic reserve, the last real vestige of actual Army divisional combat potency in the United States left to the Pentagon," compromised by sending the 3d Brigade. As Stanton wrote:
While no correlation between race and the level of neuromelanin in the substantia nigra has been reported, the significantly lower incidence of Parkinson's in blacks than in whites has "prompt[ed] some to suggest that cutaneous melanin might somehow serve to protect the neuromelanin in substantia nigra from external toxins." In addition to melanin deficiency, the molecular weight of the melanin polymer may be decreased by various factors such as oxidative stress, exposure to light, perturbation in its association with melanosomal matrix proteins, changes in pH, or in local concentrations of metal ions. A decreased molecular weight or a decrease in the degree of polymerization of ocular melanin has been proposed to turn the normally anti-oxidant polymer into a pro-oxidant. In its pro-oxidant state, melanin has been suggested to be involved in the causation and progression of macular degeneration and melanoma. Rasagiline, an important monotherapy drug in Parkinson's disease, has melanin binding properties, and melanoma tumor reducing properties. Higher eumelanin levels also can be a disadvantage, however, beyond a higher disposition toward vitamin D deficiency. Dark skin is a complicating factor in the laser removal of port-wine stains. Effective in treating white skin, in general, lasers are less successful in removing port-wine stains in people of Asian or African descent. Higher concentrations of melanin in darker-skinned individuals simply diffuse and absorb the laser radiation, inhibiting light absorption by the targeted tissue.
Smith had intended to have Dupont named Governor-General, but Queen Elizabeth II would not even consider this advice. With few exceptions, the international community backed Whitehall's assertion that Gibbs was the Queen's only legitimate representative, and hence the only lawful authority in Rhodesia. In September 1968, the Appellate Division of the High Court of Rhodesia ruled that Ian Smith's administration had become the de jure government of the country, not merely the de facto one. To support his decision, Chief Justice Sir Hugh Beadle used several statements made by Hugo Grotius, who maintained that there was no way that a nation could rightly claim to be governing a particular territory – if it was waging a war against that territory. Beadle argued that due to Britain's economic war against Rhodesia, she could not (at the same point) be described as governing Rhodesia. The ruling set the precedent that despite the UDI, the incumbent Smith government "could lawfully do anything its predecessors could lawfully have done". A Salisbury commission chaired by prominent lawyer W.R. Waley was appointed to study constitutional options open to the Rhodesian authorities as of April 1968, including on the topic of majority rule, but reopening negotiations with the British on a settlement was ruled out early on. The Waley Commission found that in practical as well as legal terms, "Europeans must surrender any belief in permanent European domination", pointing out that minority rule was not permanently sustainable.
=== Medication === Cardiovascular risk factors, such as hypercholesterolaemia, hypertension, diabetes, and smoking, are associated with a higher risk of onset and worsened course of AD. The use of statins to lower cholesterol may be of benefit in AD. Antihypertensive and antidiabetic medications in individuals without overt cognitive impairment may decrease the risk of dementia by influencing cerebrovascular pathology. Depression is associated with an increased risk for AD; management with antidepressant medications may provide a preventative measure. Historically, long-term usage of non-steroidal anti-inflammatory drugs (NSAIDs) was thought to be associated with a reduced likelihood of developing AD, as it reduces inflammation. NSAIDs do not appear to be useful as a treatment. Additionally, because women have a higher incidence of AD than men, it was once thought that estrogen deficiency during menopause was a risk factor. There is a lack of evidence to show that hormone replacement therapy (HRT) in menopause decreases the risk of cognitive decline.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
The lyophilized powder is generally stored at -20 °C or lower, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data may vary by formulation and purity.